Repurposed drugs may treat Angelman syndrome
An acne drug, a dietary supplement and a failed sleeping aid each show promise for Angelman syndrome, according to unpublished results presented Tuesday at a meeting.
An acne drug, a dietary supplement and a failed sleeping aid each show promise for Angelman syndrome, according to unpublished results presented Tuesday at a meeting.
By mapping the connections between autism genes, researchers are finding clues to the disorder’s origins. The key, they say, is to begin without bias.
Researchers can coax human stem cells to grow into layered structures that mimic the brain’s center for motor control, the cerebellum.
An overabundance of neuronal connections in the brains of people with autism may contribute to the motor impairments associated with the disorder.
Names such as autism, schizophrenia and intellectual disability are ‘umbrella’ terms that muddy the search for the true cause of an individual’s symptoms, says Eric London. He plans to come up with an alternative diagnostic scheme for developmental disabilities over the next two years.
Small pieces of RNA restore the expression of a key gene missing in Angelman syndrome and offer the promise of a highly specific cure, researchers reported Monday in Nature.
Children with autism tend to rely more on their bodies when learning new motor skills, while controls rely more on their eyes, suggests unpublished research presented Wednesday at the 2014 Society for Neuroscience annual meeting in Washington, D.C.
Children with autism and their parents share movement patterns imperceptible to the human eye, according to unpublished results presented today at the 2014 Society for Neuroscience annual meeting in Washington, D.C.
People with autism have trouble moving in response to something they see, a process tuned by the cerebellum. Researchers presented the unpublished study today at the 2014 Society for Neuroscience annual meeting in Washington, D.C. Another study presented today links defects in a section of the cerebellum to language problems in autism, underscoring the region’s importance in the disorder.
A treatment that targets the genetic defect in tuberous sclerosis prevents autism-like symptoms in mice at 6 weeks of age — the mouse equivalent of adolescence. Researchers presented the unpublished results yesterday at the 2014 Society for Neuroscience annual meeting in Washington, D.C.